Beadle C, McElroy PD, Oster CN, Beier JC, Oloo AJ, Onyango FK, et al (1995) Impact of transmission intensity and age on Plasmodium falciparum density and associated fever: implications for malaria vaccine trial design. J Infect Dis 172 (4): 1047–1054 PubMedCAS Google Scholar
Cohen S, McGregor IA, Carrington S (1961) Gammaglobulin and acquired immunity to human malaria. Nature 192: 733–737 ArticlePubMedCAS Google Scholar
Mitchell GH, Richards WH, Butcher GA, Cohen S (1977) Merozoite vaccination of douroucouli monkeys against falciparum malaria. Lancet 1 (8026): 1335–1338 ArticlePubMedCAS Google Scholar
Oliveira-Ferreira J, Daniel-Ribeiro C (2001) Protective CD8+ T cell responses against the pre-erythrocytic stages of malaria parasites: an overview. Mem Inst Oswaldo Cruz 96 (2): 221–227 ArticlePubMedCAS Google Scholar
Hirunpetcharat C, Tian JH, Kaslow DC, van Rooijen N, Kumar S, Berzofsky JA, et al (1997) Complete protective immunity induced in mice by immunization with the 19-kilodalton carboxyl-terminal fragment of the merozoite surface protein-1 (MSP1[19]) of Plasmodium yoelii expressed in Saccharomyces cerevisiae: correlation of protection with antigen-specific antibody titer, but not with effector CD4+ T cells. J Immunol 159 (7): 3400–3411 PubMedCAS Google Scholar
Mitchell GH, Richards WH, Butcher GA, Cohen S (1977) Merozoite vaccination of douroucouli monkeys against falciparum malaria. Lancet 1 (8026): 1335–1338 ArticlePubMedCAS Google Scholar
Mueller AK, Labaied M, Kappe SH, Matuschewski K (2005) Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature 433 (7022): 164–167 ArticlePubMedCAS Google Scholar
Clyde DF, Most H, McCarthy VC, Vanderberg JP (1973) Immunization of man against sporozite-induced falciparum malaria. Am J Med Sci 266 (3): 169–177 ArticlePubMedCAS Google Scholar
Clyde DF (1975) Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites. Am J Trop Med Hyg 24 (3): 397–401 PubMedCAS Google Scholar
Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Milman J, et al (2004) Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 364 (9443): 1411–1420 ArticlePubMedCAS Google Scholar
Bojang KA, Milligan PJ, Pinder M, Vigneron L, Alloueche A, Kester KE, et al (2001) Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 358 (9297): 1927–1934 ArticlePubMedCAS Google Scholar
Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, Desmons P, et al (1997) A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med 336 (2): 86–91 ArticlePubMedCAS Google Scholar
Targett GA (2005) Malaria vaccines 1985–2005: a full circle? Trends Parasitol 21 (11): 499–503 ArticlePubMedCAS Google Scholar
Moreno R, Poltl-Frank F, Stuber D, Matile H, Mutz M, Weiss NA, et al (2001) Rhoptry-associated protein 1-binding monoclonal antibody raised against a heterologous peptide sequence inhibits Plasmodium falciparum growth in vitro. Infect Immun 69 (4): 2558–2568 ArticlePubMedCAS Google Scholar
Nwuba RI, Sodeinde O, Anumudu CI, Omosun YO, Odaibo AB, Holder AA, et al (2002) The human immune response to Plasmodium falciparum includes both antibodies that inhibit merozoite surface protein 1 secondary processing and blocking antibodies. Infect Immun 70 (9): 5328–5331 ArticlePubMedCAS Google Scholar
Guevara Patino JA, Holder AA, McBride JS, Blackman MJ (1997) Antibodies that inhibit malaria merozoite surface protein-1 processing and erythrocyte invasion are blocked by naturally acquired human antibodies. J Exp Med 186 (10): 1689–1699 ArticlePubMedCAS Google Scholar
Uthaipibull C, Aufiero B, Syed SE, Hansen B, Guevara Patino JA, Angov E, et al (2001) Inhibitory and blocking monoclonal antibody epitopes on merozoite surface protein 1 of the malaria parasite Plasmodium falciparum. J Mol Biol 307 (5): 1381–1394 ArticlePubMedCAS Google Scholar
Egan AF, Chappel JA, Burghaus PA, Morris JS, McBride JS, Holder AA, et al (1995) Serum antibodies from malaria-exposed people recognize conserved epitopes formed by the two epidermal growth factor motifs of MSP1 (19), the carboxy-terminal fragment of the major merozoite surface protein of Plasmodium falciparum. Infect Immun 63 (2): 456–466 PubMedCAS Google Scholar
Wang L, Black CG, Marshall VM, Coppel RL (1999) Structural and antigenic properties of merozoite surface protein 4 of Plasmodium falciparum. Infect Immun 67 (5): 2193–2200 PubMedCAS Google Scholar
Schild H, Rammensee HR (1996) Peptide based vaccines. In: Kaufmann SHE (ed) Concepts in vaccine development. Walter de Gruyter, Berlin Google Scholar
Gilbert SC, Plebanski M, Harris SJ, Allsopp CE, Thomas R, Layton GT, et al (1997) A protein particle vaccine containing multiple malaria epitopes. Nat Biotechnol 15 (12): 1280–1284 ArticlePubMedCAS Google Scholar
Gilbert SC, Hill AV (1997) Protein particle vaccines against malaria. Parasitol Today 13 (8): 302–306 ArticlePubMedCAS Google Scholar
Birkett A, Lyons K, Schmidt A, Boyd D, Oliveira GA, Siddique A, et al (2002) A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts. Infect Immun 70 (12): 6860–6870 ArticlePubMedCAS Google Scholar
Gilbert SC, Plebanski M, Harris SJ, Allsopp CE, Thomas R, Layton GT, et al (1997) A protein particle vaccine containing multiple malaria epitopes. Nat Biotechnol 15 (12): 1280–1284 ArticlePubMedCAS Google Scholar
Tsurudome M, Gluck R, Graf R, Falchetto R, Schaller U, Brunner J (1992) Lipid interactions of the hemagglutinin HA2 NH2-terminal segment during influenza virus-induced membrane fusion. J Biol Chem 267 (28): 20225–20232 PubMedCAS Google Scholar
Ollivon M, Lesieur S, Grabielle-Madelmont C, Paternostre M (2000) Vesicle reconstitution from lipid-detergent mixed micelles. Biochim Biophys Acta 1508 (1–2): 34–50 PubMedCAS Google Scholar
Zurbriggen R, Novak-Hofer I, Seelig A, Gluck R (2000) IRIV-adjuvanted hepatitis A vaccine: in vivo absorption and biophysical characterization. Prog Lipid Res 39 (1): 3–18 ArticlePubMedCAS Google Scholar
Amacker M, Engler O, Kammer AR, Vadrucci S, Oberholzer D, Cerny A, et al (2005) Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic T cells. Int Immunol 17 (6): 695–704 ArticlePubMedCAS Google Scholar
Hunziker IP, Grabscheid B, Zurbriggen R, Gluck R, Pichler WJ, Cerny A (2002) In vitro studies of core peptidebearing immunopotentiating reconstituted influenza virosomes as a non-live prototype vaccine against hepatitis C virus. Int Immunol 14 (6): 615–626 ArticlePubMedCAS Google Scholar
Clyde DF, Most H, McCarthy VC, Vanderberg JP (1973) Immunization of man against sporozite-induced falciparum malaria. Am J Med Sci 266 (3): 169–177 ArticlePubMedCAS Google Scholar
Egan JE, Hoffman SL, Haynes JD, Sadoff JC, Schneider I, Grau GE, et al (1993) Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites. Am J Trop Med Hyg 49 (2): 166–173 PubMedCAS Google Scholar
Sinnis P, Nussenzweig V (1996) Preventing sporozoite invasion of hepatocytes. In: Hoffman SL (ed) Malaria vaccine development. American Society for Microbiology, Washington DC, pp 15–33 Google Scholar
Herrington D, Davis J, Nardin E, Beier M, Cortese J, Eddy H, et al (1991) Successful immunization of humans with irradiated malaria sporozoites: humoral and cellular responses of the protected individuals. Am J Trop Med Hyg 45 (5): 539–547 PubMedCAS Google Scholar
Nussenzweig RS, Nussenzweig V (1989) Antisporozoite vaccine for malaria: experimental basis and current status. Rev Infect Dis 11 [Suppl 3]: S579–S585 PubMed Google Scholar
Zavala F, Masuda A, Graves PM, Nussenzweig V, Nussenzweig RS (1985) Ubiquity of the repetitive epitope of the CS protein in different isolates of human malaria parasites. J Immunol 135 (4): 2790–2793 PubMedCAS Google Scholar
Herrington DA, Clyde DF, Losonsky G, Cortesia M, Murphy JR, Davis J, et al (1987) Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature 328 (6127): 257–259 ArticlePubMedCAS Google Scholar
Moreno R, Jiang L, Moehle K, Zurbriggen R, Gluck R, Robinson JA, et al (2001) Exploiting conformationally constrained peptidomimetics and an efficient human-compatible delivery system in synthetic vaccine design. Chembiochem 2 (11): 838–843 ArticlePubMedCAS Google Scholar
Pfeiffer B, Peduzzi E, Moehle K, Zurbriggen R, Gluck R, Pluschke G, et al (2003) A virosome-mimotope approach to synthetic vaccine design and optimization: synthesis, conformation, and immune recognition of a potential malaria-vaccine candidate. Angew Chem Int Ed Engl 42 (21): 2368–2371 ArticlePubMedCAS Google Scholar
Mahanty S, Saul A, Miller LH (2003) Progress in the development of recombinant and synthetic blood-stage malaria vaccines. J Exp Biol 206 (Pt 21): 3781–3788 ArticlePubMedCAS Google Scholar
Hodder AN, Crewther PE, Anders RF (2001) Specificity of the protective antibody response to apical membrane antigen 1. Infect Immun 69 (5): 3286–3294 ArticlePubMedCAS Google Scholar
Kocken CH, Narum1 DL, Massougbodji A, Ayivi B, Dubbeld MA, van der WA, et al (2000) Molecular characterisation of Plasmodium reichenowi apical membrane antigen-1 (AMA-1), comparison with P. falciparum AMA-1, and antibody-mediated inhibition of red cell invasion. Mol Biochem Parasitol 109 (2): 147–156 ArticlePubMedCAS Google Scholar
Anders RF, Crewther PE, Edwards S, Margetts M, Matthew ML, Pollock B, et al (1998) Immunisation with recombinant AMA-1 protects mice against infection with Plasmodium chabaudi. Vaccine 16 (2–3): 240–247 ArticlePubMedCAS Google Scholar
Howell SA, Withers-Martinez C, Kocken CH, Thomas AW, Blackman MJ (2001) Proteolytic processing and primary structure of Plasmodium falciparum apical membrane antigen-1. J Biol Chem 276 (33): 31311–31320 ArticlePubMedCAS Google Scholar
Nair M, Hinds MG, Coley AM, Hodder AN, Foley M, Anders RF, et al (2002) Structure of domain III of the blood-stage malaria vaccine candidate, Plasmodium falciparum apical membrane antigen 1 (AMA1). J Mol Biol 322 (4): 741–753 ArticlePubMedCAS Google Scholar
Hodder AN, Crewther PE, Matthew ML, Reid GE, Moritz RL, Simpson RJ, et al (1996) The disulfide bond structure of Plasmodium apical membrane antigen-1. J Biol Chem 271 (46): 29446–29452 ArticlePubMedCAS Google Scholar
Mueller MS, Renard A, Boato F, Vogel D, Naegeli M, Zurbriggen R, et al (2003) Induction of parasite growthinhibitory antibodies by a virosomal formulation of a peptidomimetic of loop I from domain III of Plasmodium falciparum apical membrane antigen 1. Infect Immun 71 (8): 4749–4758 ArticlePubMedCAS Google Scholar
Zurbriggen R, Gluck R (1999) Immunogenicity of IRIV-versus alum-adjuvanted diphtheria an tetanus toxoid vaccnes in influenza primed mice. Vaccine 17 (11–12): 1301–1305 ArticlePubMedCAS Google Scholar
Zurbriggen R, Gluck R (1999) Immunogenicity of IRIV-versus alum-adjuvanted diphtheria an tetanus toxoid vaccnes in influenza primed mice. Vaccine 17 (11–12): 1301–1305 ArticlePubMedCAS Google Scholar
Poltl-Frank F, Zurbriggen R, Helg A, Stuart F, Robinson J, Gluck R, et al (1999) Use of reconstituted influenza virus virosomes as an immunopotentiating delivery system for a peptide-based vaccine. Clin Exp Immunol 117 (3): 496–503 ArticlePubMedCAS Google Scholar
Herrington DA, Clyde DF, Losonsky G, Cortesia M, Murphy JR, Davis J, et al (1987) Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature 328 (6127): 257–259 ArticlePubMedCAS Google Scholar
Stephens R, Langhorne J (2006) Priming of CD4+ T cells and development of CD4+ T cell memory; lessons for malaria. Parasite Immunol 28 (1–2): 25–30 ArticlePubMedCAS Google Scholar
Rieckmann KH (1990) Human immunization with attenuated sporozoites. Bull World Health Organ 68 [Suppl]: 13–16 PubMed Google Scholar